Here is a scenario that plays out more often than anyone in this industry likes to admit. A founding team spends four years developing a device. They run the clinical study. They file the 510(k). They get cleared. They hire their first two sales reps, set up shop at a major conference, and start calling on hospitals.
Then a procurement officer asks a simple question: “What code does the physician bill with?” The founder does not have a clean answer. And that is when the real work begins, two years after it should have started.
This is the CPT code for a medical device problem. It is not a billing detail. It is a commercialization risk that compounds quietly in the background while your regulatory team is focused on the submission, your clinical team is running the study, and your investors are watching the clearance timeline.
First, what you are actually dealing with
CPT codes, Current Procedural Terminology, are five-digit numeric codes managed by the American Medical Association. Every medical procedure performed in the United States gets assigned one. They are what physicians and facilities use to tell insurers what they did and to request payment.
Without a relevant CPT code for medical device procedures, there is no standardized billing pathway. Without a billing pathway, hospitals and physician practices face significant administrative friction in adopting your device, even if the clinical case is strong, even if surgeons love it. Even if the outcomes data are compelling. Reimbursement is not a downstream problem. It is infrastructure. And like all infrastructure, it takes years to build. There are three billing structures MedTech founders need to understand.
Category I CPT codes are permanent. They are the gold standard when it comes to getting a CPT code for medical device procedures that are widely adopted, supported by substantial clinical evidence, and already in common use. Obtaining one realistically takes three to six years from the point of FDA clearance. These are the codes that drive sustainable commercial scale.
Category III CPT codes are temporary tracking codes created by the AMA specifically for emerging technologies. They move faster, typically six to twelve months from application. But here is what founders frequently misunderstand: a Category III code does not come with reimbursement attached. Insurers are not required to pay for procedures billed under Category III. Some will. Many will not. The code is a data collection mechanism, a bridge, not a destination.
HCPCS codes, managed by CMS rather than the AMA, apply to durable medical equipment and supplies rather than physician-performed procedures. If your device is something a patient takes home and uses independently, this is likely your pathway. If it is used in a clinical procedure, CPT is where you need to be.
Knowing which of these applies to your device, and when to pursue each, is the first strategic decision. Most founding teams get to it eighteen months later than they should.
Applying for a CPT code for a medical device, step by step
Start by searching for what already exists
Before you apply for anything, find out whether a billable code already covers the procedure your device enables. Many founders who start researching how to get a CPT code for a medical device discover that an existing code partially applies. This is not as simple as running a keyword search. CPT code descriptions can be written broadly enough to cover more than they appear to on the surface, or narrowly enough to exclude procedures that seem like obvious fits.
Bring in someone who reads CPT language professionally. A reimbursement consultant who has worked with the AMA panel directly will tell you in one conversation what would take months of independent research to figure out. If an existing code works, even imperfectly, that creates a faster commercialization path while you build toward a dedicated code. If nothing fits, you move to the application.
Applying for a Category III code
The AMA CPT Editorial Panel convenes three times per year. Applications go through the AMA’s Smart App and need to make a clear case that the procedure is clinically distinct from anything currently coded, that your device has a regulatory pathway in place, and that there is preliminary evidence of safety and clinical utility. This is the formal mechanism through which most companies begin the process of obtaining a CPT code for medical device procedures in the emerging technology space.
Missing a filing deadline costs you a full cycle, roughly four months. If your application is incomplete or the procedure description is ambiguous, you get pushed back. Run a tight process here. Once granted, Category III codes are valid for five years. That window is your runway to generate the evidence you will need for Category I.
Build clinical evidence for two audiences simultaneously
This is where the strategy gets complicated and where most early-stage companies underinvest.
FDA clearance through the 510(k) pathway requires demonstrating substantial equivalence to a predicate device. The evidentiary bar is about safety and functional performance relative to something that already exists on the market. Payers have an entirely different frame. They want to see that your device changes clinical decision-making, leads to meaningfully better outcomes, and either reduces the cost of care or delivers value that justifies its price. These are not the same question. And the clinical study you design to answer one question will often leave critical gaps when it comes to the other.
The medtech companies that move fastest through the reimbursement process design their studies from the start to generate data that works for both audiences. That means involving a health economics team before your protocol is finalized. It means thinking through what a medical director at a major commercial payer will ask when they review your dossier three years from now, and making sure your current study will have an answer.
Specialty societies carry more weight than most founders expect
The AMA Editorial Panel does not make decisions in isolation. It relies heavily on input from the specialty societies whose members will perform procedures using your device. An application that arrives with the endorsement of a relevant professional society carries substantially more weight than one that does not.
This is relationship work. It takes time. Start identifying which societies are relevant to your therapeutic area early, ideally during development, not post-clearance. Find the two or three key opinion leaders who have genuine credibility within those societies and who see real clinical value in what you are building. Their voice in publications, at conferences, and eventually in formal society endorsements will shape your timeline more than most founders realize.
Specialty society engagement is also where the regulatory and commercial worlds tend to collide productively. A physician who is vocal about unmet clinical needs in a specific area, and who connects that need to your device publicly, creates both market awareness and policy momentum.
Moving from Category III to Category I
Category I applications require a much higher evidentiary standard: peer-reviewed published data, demonstrated procedural volume across multiple institutions, and formal specialty society support. The AMA reviews Category I applications annually.
From Category III grant to Category I approval, realistic timelines run two to five years depending on the pace of clinical adoption, the strength of your evidence, and how actively you have cultivated your relationships within the relevant specialty.
The companies that compress this timeline are the ones that treated Category III as a launch pad, not a finish line. They used the period strategically to publish data, run real-world studies, track utilization patterns, and build the dossier that the AMA panel will eventually evaluate.
Where founders consistently lose time
They start the reimbursement conversation after clearance. The regulatory team crosses the finish line, and then someone asks what the billing pathway looks like. At that point, you are already eighteen months behind where you need to be. Knowing how to get a CPT code for a medical device adoption starts well before the 510(k) is filed, not after it is cleared.
They design one clinical study and expect it to serve two masters. FDA and payers are not asking the same questions. A 510(k) study built around substantial equivalence will rarely generate the outcomes data a payer wants to see. Both tracks need to be addressed at the design stage.
They assume Category III means they are reimbursed. It does not. A code and coverage are different things. Once you have a Category III code, the real work of payer engagement begins. Each major insurer makes its own coverage determination, on its own timeline, based on its own evidence review. This is not a one-time event. It is an ongoing campaign.
They underestimate how much specialty society relationships matter. The AMA process is not purely bureaucratic. It responds to clinical community signals. Building those relationships after you have a product to sell is too late to be effective.
The timeline you should be planning around
| Peer-reviewed data published | Realistic Timeframe |
|---|---|
| Category III code granted | 6 to 12 months post-application |
| First payer coverage decisions under Category III | 12 to 24 months post code |
| Peer-reviewed data published | 18 to 36 months post clearance |
| Category I application submitted | 3 to 5 years post clearance |
| Category I code granted | 4 to 7 years post clearance |
| Broad commercial payer coverage | 5 to 9 years post clearance |
These numbers are not meant to be discouraging. They are meant to be calibrating. Understanding the realistic timeline for obtaining a CPT code for medical device procedures is one of the most valuable things a founding team can do early. The founders who build their commercialization strategy around these timelines make better decisions about hiring, pricing, cash flow, and fundraising than those who discover the timeline after the fact.
What this actually means for your commercial strategy
Reimbursement planning is not a regulatory function or a billing function. It sits at the intersection of clinical strategy, market access, and commercial planning, and it needs someone in the room who understands all three. The devices that achieve broad US adoption are the ones whose founders treated getting a CPT code for a medical device reimbursement as a parallel workstream from day one, not a problem to solve after clearance. They designed their clinical studies to generate the right data. They engaged specialty societies before they needed them. They went into payer conversations with a value story built on outcomes, not just technology.
If you are a European medical device company working through your US market entry strategy and you need to think through how getting a CPT code for a medical device fits into your current roadmap, this is exactly the kind of work Aura Health focuses on.